Technical analysis of Century Therapeutics, Inc. (IPSC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Price Performance
| 1 month | +1.02% |
| 3 months | -13.54% |
| Year-to-date | +99.03% |
| 1 year | +302.52% |
| 3 years | -11.61% |
| 5 years | -92.00% |
52-Week Range
| 52-week High | $3.04 |
| 52-week Low | $0.43 |
| Avg Volume (90d) | 1.0M |
Technical Indicators
| SMA 50 | $2.09 |
| SMA 200 | $1.99 |
| Beta | 1.67 |
| 30-day Volatility (annualised) | 53.9% |
| Price vs SMA 50 | -5.2% |
| Price vs SMA 200 | -0.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $0.58 | |
| 2025-11 | $0.55 | -6.5% |
| 2025-12 | $0.99 | +82.4% |
| 2026-01 | $1.90 | +91.0% |
| 2026-02 | $2.32 | +22.1% |
| 2026-03 | $2.26 | -2.6% |
| 2026-04 | $2.29 | +1.3% |
| 2026-05 | $2.45 | +7.0% |
| 2026-06 | $2.45 | +0.0% |
| 2026-07 | $2.02 | -17.6% |
| 2026-08 | $2.05 | +1.5% |
| 2026-09 | $1.98 | -3.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-11 | | |
| 2026-09-11 | $-39.98 | |
| 2026-09-11 | $-0.02 | $22M |
| 2026-09-11 | $0.44 | $14M |
| 2026-09-11 | | |
| 2026-09-11 | | |
Price
| Price | $1.86 |
| Market Cap | $161M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.54 |
| EV / EBITDA | -1.61 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 8.28 |